Gastrointestinal stromal tumor mesenchymal neoplasms: The offspring that choose the wrong path

Journal of Multidisciplinary Healthcare

Volumn 6, Issue , 2013, Pages 127-131

  Machairiotis, Nikolaos ^a   Kougioumtzi, Ioanna ^a   Zarogoulidis, Paul ^b   Stylianaki, Aikaterini ^a   Tsimogiannis, Konstantinos ^c   Katsikogiannis, Nikolaos ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Cancer pathways; GIST; Interstitial cells of cajal; Mesenchymal stem cells; PDGFR

Indexed keywords

ADENOSINE TRIPHOSPHATE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EDEMA; ENDOSCOPIC SURGERY; ENZYME INHIBITION; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE LOCATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LAPAROSCOPIC SURGERY; MUSCLE CRAMP; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE C KIT; OVERALL SURVIVAL; PLATELET DERIVED GROWTH FACTOR ALPHA GENE; PROGENY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84876106034     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S43703     Document Type: Article

References (34)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259-1269.
2. Blay JY. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 2011;37(5):373-384.
3. De Vogelaere K, Hoorens A, Haentjens P, Delvaux G. Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach. Surg Endosc. Epub December 12, 2012.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-580.
5. Badalamenti G, Rodolico V, Fulfaro F, et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007;18 Suppl 6:vi136-vi140.
6. Bai CG, Hou XW, Wang F, et al. Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. World J Gastroenterol. 2012;18(23):2929-2937.
7. Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D. Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol. 2012;5:21.
8. Wong NA, Deans ZC, Ramsden SC. The UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation. J Clin Pathol. 2012;65(9):786-790.
9. Suzuki K, Kaneko G, Kubota K, et al. Malignant tumor, of the gastrointestinal stromal tumor type, in the greater omentum. J Gastroenterol. 2003;38(10):985-988.
10. Lasota J, Kuban W, Wardelmann E, et al. KIT codon 558 insertions in gastrointestinal stromal tumors. Analysis of 17 rare KIT mutants. Hum Pathol. 2008;39(12):1728-1736.
11. Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2009;15(24):7510-7518.
12. Debiec-Rychter M, Dumez H, Judson I, et al; EORTC Soft Tissue and Bone Sarcoma Group.Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer.2004;40(5):689-695.
13. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-4349.
14. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182-4190.
15. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764-4774.
16. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6(4):249-251.
17. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 Pt 1):5398-5405.
18. Nishida T, Kanda T, Nishitani A, et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 2008;99(4):799-804.
19. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52-68.
20. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22): 5336-5339.
21. Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol. 2012;2012:595968.
22. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1): 51-58.
23. Jeong IH, Kim JH, Lee SR, et al. Minimally invasive treatment of gastric gastrointestinal stromal tumors: laparoscopic and endoscopic approach. Surg Laparosc Endosc Percutan Tech. 2012;22(3):244-250.
24. Karanikas M, Machairiotis N, Zarogoulidis P, et al. Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions. Onco Targets Ther. 2012;5:433-438.
25. Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol. 2009;6(6):363-371.
26. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/ adjuvant imatinib mesylate for advanced primary and metastatic/ recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19(4):1074-1080.
27. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626-632.
28. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134.
29. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.
30. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000;46(1):88-92.
31. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14(1):14-24.
32. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013;11(1):60-66.
33. Patrikidou A, Chabaud S, Ray-Coquard I, et al; For the French Sarcoma Group. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol. Epub November 21, 2012.
34. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/ adjuvant imatinib mesylate (IM) for advanced primary and metastatic/ recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-47.